Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Abstract

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Drugs In Development, 2022, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 8, 2, 10 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Content

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Allergic Conjunctivitis - Overview
Allergic Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Allergic Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Allergic Conjunctivitis - Companies Involved in Therapeutics Development
Accolade Pharmaceuticals LLC
Aldeyra Therapeutics Inc
Alexion Pharmaceuticals Inc
ALK-Abello AS
Allakos Inc
Boehringer Ingelheim International GmbH
Clevexel Pharma SA
Faes Farma SA
IACTA Pharmaceuticals Inc
Intas Pharmaceuticals Ltd
JW Pharmaceutical Corp
Kissei Pharmaceutical Co Ltd
Nanomerics Ltd
NicOx SA
Ocular Therapeutix Inc
OKYO Pharma Ltd
Oyster Point Pharma Inc
Quark Pharmaceuticals Inc
RAPT Therapeutics Inc
Satellos Bioscience Inc
SIFI SpA
Siolta Therapeutics Inc
Sylentis SAU
Vanda Pharmaceuticals Inc
Wuhan Yicheng Biotechnology Co Ltd
Allergic Conjunctivitis - Drug Profiles
bertilimumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
bilastine - Drug Profile
Product Description
Mechanism Of Action
History of Events
birch pollen allergen extract - Drug Profile
Product Description
Mechanism Of Action
cetirizine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinastine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
IC-265 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IC-270 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KCE-210 - Drug Profile
Product Description
Mechanism Of Action
ketotifen SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
lipidated tacrolimus - Drug Profile
Product Description
Mechanism Of Action
lirentelimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
NM-134 - Drug Profile
Product Description
Mechanism Of Action
OC-103 - Drug Profile
Product Description
Mechanism Of Action
OKYO-0101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PH-006 - Drug Profile
Product Description
Mechanism Of Action
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
History of Events
QPI-1020R - Drug Profile
Product Description
Mechanism Of Action
reproxalap - Drug Profile
Product Description
Mechanism Of Action
History of Events
RPT-193 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
STMC-103H - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYL-116011 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VSJ-110 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Yipiwutai - Drug Profile
Product Description
Mechanism Of Action
Zafi-2 - Drug Profile
Product Description
Mechanism Of Action
Allergic Conjunctivitis - Dormant Projects
Allergic Conjunctivitis - Discontinued Products
Allergic Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Mar 01, 2022: Nicox’s partner Ocumension obtains positive phase 3 clinical trial results for ZERVIATE in China
Feb 01, 2022: Aldeyra Therapeutics announces publication of phase 2 clinical trial of reproxalap in allergen chamber model
Jan 05, 2022: Nicox European patent seals ZERVIATE major market coverage to 2030
Jul 05, 2021: Nicox to receive $2 million from Ocumension Therapeutics as advance milestone payment under ZERVIATE agreement
Apr 27, 2021: Aldeyra Therapeutics achieves statistical significance for primary endpoint and all secondary endpoints in phase 3 INVIGORATE clinical trial of Reproxalap in allergic conjunctivitis
Apr 26, 2021: Aldeyra Therapeutics schedules conference call and webcast to announce top-line results from the phase 3 INVIGORATE clinical trial
Dec 30, 2020: Nicox’s partner Ocumension Therapeutics initiates ZERVIATE phase 3 clinical trial in China
Oct 26, 2020: Vanda Pharmaceuticals receives FDA approval to proceed with Investigational New Drug VSJ-110 for allergic conjunctivitis
Oct 22, 2020: Aldeyra to present new Reproxalap data from phase 2 clinical trial in allergic conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting
Sep 22, 2020: Nicox’s ZERVIATE receives IND approval in China
May 21, 2020: Allakos announces multiple presentations related to eosinophil and mast cell-driven diseases at the digital EAACI Annual Congress 2020
May 11, 2020: Allakos announces a presentation of antolimab in patients with severe allergic conjunctivitis at the 2020 ASCRS Virtual Annual Meeting
Mar 30, 2020: Eyevance Pharmaceuticals launches ZERVIATE in the United States
Feb 24, 2020: Aldeyra Therapeutics to provide update on late-stage clinical development pipeline at 2020 Research & Development Day
Jan 22, 2020: Aldeyra Therapeutics begins enrolment in allergic conjunctivitis study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Allergic Conjunctivitis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals LLC, 2022
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, 2022
Allergic Conjunctivitis - Pipeline by Alexion Pharmaceuticals Inc, 2022
Allergic Conjunctivitis - Pipeline by ALK-Abello AS, 2022
Allergic Conjunctivitis - Pipeline by Allakos Inc, 2022
Allergic Conjunctivitis - Pipeline by Boehringer Ingelheim International GmbH, 2022
Allergic Conjunctivitis - Pipeline by Clevexel Pharma SA, 2022
Allergic Conjunctivitis - Pipeline by Faes Farma SA, 2022
Allergic Conjunctivitis - Pipeline by IACTA Pharmaceuticals Inc, 2022
Allergic Conjunctivitis - Pipeline by Intas Pharmaceuticals Ltd, 2022
Allergic Conjunctivitis - Pipeline by JW Pharmaceutical Corp, 2022
Allergic Conjunctivitis - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Allergic Conjunctivitis - Pipeline by Nanomerics Ltd, 2022
Allergic Conjunctivitis - Pipeline by NicOx SA, 2022
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, 2022
Allergic Conjunctivitis - Pipeline by OKYO Pharma Ltd, 2022
Allergic Conjunctivitis - Pipeline by Oyster Point Pharma Inc, 2022
Allergic Conjunctivitis - Pipeline by Quark Pharmaceuticals Inc, 2022
Allergic Conjunctivitis - Pipeline by RAPT Therapeutics Inc, 2022
Allergic Conjunctivitis - Pipeline by Satellos Bioscience Inc, 2022
Allergic Conjunctivitis - Pipeline by SIFI SpA, 2022
Allergic Conjunctivitis - Pipeline by Siolta Therapeutics Inc, 2022
Allergic Conjunctivitis - Pipeline by Sylentis SAU, 2022
Allergic Conjunctivitis - Pipeline by Vanda Pharmaceuticals Inc, 2022
Allergic Conjunctivitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2022
Allergic Conjunctivitis - Dormant Projects, 2022
Allergic Conjunctivitis - Dormant Projects, 2022 (Contd..1)
Allergic Conjunctivitis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Allergic Conjunctivitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022